Abstract: Objective： To evaluate the safety of dutasteride in the treatment of benign prostatic hyperplasia(BPH) with the control group of placebo. Methods：The meta-analysis included data from the RCTs about the safety of dutasteride from the databases such as CNKI， CBM， CMCC， VIP， WANFANG， PubMed， Ovid， EMBASE， Science Direct， EBSCO and Elsevier. Meta-analysis on the slected literature was conducted by means of Review Manager 5.2 software. Results： Four papers were included in Meta-analysis of drug-related adverse reaction rates and five papers were included in the loss of libido and erectile dysfunction (impotence) incidence analysis.The OR values were 1.21(95%CI:0.82~1.78，P=0.33)，1.77(95%CI:0.83~3.78，P=0.14) and 1.40(95%CI:0.87~2.25，P=0.16) in the drug-related adverse reaction rates analysis， loss of libido incidence analysis and erectile dysfunction (impotence) incidence analysis respectively. Conclusion： There is no significant difference in the incidence of drug-related adverse reactions， loss of libido and erectile dysfunction (impotence) between the placebo group and the dutasteride group. Dutasteride has favorable safety in the treatment of BPH.